Abigail Dirks, MS

Abigail Dirks, MS, Tufts Center for the Study of Drug Development, Tufts University School of Medicine

Articles by Abigail Dirks, MS

© FlowStudio - © FlowStudio - stock.adobe.com

Quantifying the Net Financial Value of Deploying Risk-Based Quality Management

June 11th 2026

A Tufts CSDD study quantifies risk-based quality management's net financial value at $13.8 million per Phase III oncology trial, with ROI multiples up to 22.7x driven primarily by cycle time reductions rather than monitoring cost savings.

Vaccine developers must transition from episodic and reactive engagement to deliberate, enterprise-level patient-engagement strategies embedded within development and commercialization planning and implementation. Credit: Stock.Adobe.com/weyo

Patient Engagement Practices Informing Strategies to Address Vaccine Hesitancy

ByHana Do, MPH,Madison Ford, MPH,Abigail Dirks, MS,Kenneth Getz, MBA

March 16th 2026

Analysis from the Tufts Center for the Study of Drug Development suggests that transparency in clinical evidence, community engagement, and more representative clinical trials are key factors associated with faster vaccine adoption and improved public trust.